CLINICAL_TRIALS
trial_result
· 2019-07-30
Clinical Trial Update: A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis [Phase 2]
Summary
A Phase II study of bermekimab (MABp1) in moderate to severe atopic dermatitis has completed with results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Janssen Research & Development, LLC | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2019-07-30